Cellebrite Misses ARR Target, Cuts Guidance, Swaps CEO
Cellebrite's Q2 ARR fell below its own projection range, triggering a $15M guidance cut and an immediate CEO change, causing a 29% stock drop.
Key points
- Cellebrite's Q2 ARR of $507.8 million missed the company's own $510M-$513M projection range.
- The company cut full-year ARR guidance by $15 million due to cloud permit delays.
- Shares fell 29% to $10.80 after the earnings report and immediate CEO swap.
Cellebrite DI Ltd. reported second-quarter Annual Recurring Revenue of $507.8 million, falling below the lower bound of its previously projected range of $510 million to $513 million. The company simultaneously reduced its full-year ARR guidance by approximately $15 million at the midpoint, citing regulatory delays in cloud technology deals. This guidance adjustment and revenue miss followed the abrupt replacement of CEO Tom Hogan with Shiv Ramji, effective immediately upon the announcement.
The market reaction to these disclosures was severe. On August 13, 2026, Cellebrite shares declined by $4.45, a drop of 29 percent, to close at $10.80 per share. The company attributed the guidance cut to a foreign entity permit requirement applied to cloud technology, which it stated delayed certain commercial transactions. This operational hurdle appears to have directly impacted the company’s ability to meet its initial revenue targets for the period.
Legal Probe Opens After Missed Targets
In response to the company's performance and leadership changes, Kaplan Fox & Kilsheimer LLP has launched an investigation into potential securities violations. The firm is contacting investors who may have suffered losses during the relevant period to assess their claims. According to The Globe and Mail, the law firm is seeking information that could assist in determining whether the company’s disclosures and guidance were accurate at the time they were made to the public.
The investigation focuses on the period surrounding the August 13, 2026, earnings release. Kaplan Fox, a litigation firm founded in 1956, specializes in complex securities and antitrust actions. The firm is reviewing the specifics of the ARR miss and the subsequent guidance reduction to evaluate potential legal liability for the company and its executives. Investors are being encouraged to contact the firm directly to provide details about their holdings and the timing of their trades.
Regulatory Hurdles Impact Cloud Revenue
The primary operational driver for the reduced guidance was a specific regulatory constraint. Cellebrite identified a foreign entity permit requirement that applies to cloud technology services as a factor delaying key deals. This regulatory friction prevented the company from closing transactions that were originally expected to contribute to the higher end of its revenue projections. The impact of this delay was significant enough to warrant a downward revision of the full-year outlook by roughly $15 million.
The simultaneous announcement of the CEO change compounded the negative sentiment in the stock market. Shiv Ramji assumed the role of chief executive officer immediately, succeeding Tom Hogan. The combination of a missed quarterly target, a significant cut to annual expectations, and a sudden leadership transition created a sharp negative event for shareholders. The 29 percent drop in share price reflects the immediate market reassessment of the company’s operational stability and future earnings potential.
